Andres Splenser, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1609910835
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $859,770 of the $922,619 with a category attached, or 93.2%. 44 manufacturers reported payments, led by Lilly USA, LLC at 56.1% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,814 payments — averaging $508.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$517K
- Novo Nordisk$326K
- Merck$27K
- Madrigal Pharmaceuticals$22K
- Sanofi-aventis U.S. LLC$22K
- Bayer$3K
- plus $6K from 38 others
What the payments were for
- Consulting fees$9,1081%
- Speaking & faculty fees$859,77093%
- Travel & lodging$33,8714%
- Food & beverage$19,7592%
- Education$520%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$262,364
- TRULICITY$214,684
- Ozempic$179,867
- RYBELSUS$108,018
- STEGLATRO$25,693
- Xultophy 100/3.6$23,355
- REZDIFFRA$21,856
- LYUMJEV$11,177
- SOLIQUA 100/33$9,333
- TOUJEO$7,531
- Tresiba$4,539
- Non-Covered$3,200
- Victoza$1,485
How this compares
$922,619 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 268 | $434,655 |
| OzempicSemaglutide | 198 | $319,669 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 69 | $102,261 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 69 | $70,073 |
| JardianceEmpagliflozin | 48 | $59,332 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $55,014 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 24 | $44,368 |
| MounjaroTirzepatide | 30 | $43,765 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $37,585 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $34,519 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $18,709 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $10,718 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 95 | $10,115 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $9,328 |
| SynthroidLevothyroxine Sodium | 78 | $8,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $517,477 | $478,420298 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $325,505 | $364,038222 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $170 | $161,593117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $21,558 | $70,07369 claims |
| AbbVieSynthroid, Armour Thyroid | $348 | $10,822102 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $455 | $5,711357 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $69 | $83115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.